Skip to Main Content

Intracellular Therapeutics Pipeline

Diverse and Expanding Pipeline of Programs Spanning Discovery and Clinical Development

At Entrada Therapeutics, we are driven to transform the lives of patients by establishing a new class of intracellular therapeutics. We are already developing potential treatments across multiple devastating diseases with a simple and scalable EEV platform designed to translate from preclinical to clinical development.

Learn more about our proprietary EEV™ Platform.

Duchenne Muscular Dystrophy (DMD)

ENTR-601-44 (Exon 44 Skipping Oligonucleotide)

Duchenne Muscular Dystrophy
Discovery 100% complete
Lead Optimization 100% complete
IND Enabling 100% complete
Clinical 22% complete

ENTR-601-45 (Exon 45 Skipping Oligonucleotide)

Duchenne Muscular Dystrophy
Discovery 100% complete
Lead Optimization 100% complete
IND Enabling 100% complete
Clinical 5% complete

ENTR-601-50 (Exon 50 Skipping Oligonucleotide)

Duchenne Muscular Dystrophy
Discovery 100% complete
Lead Optimization 100% complete
IND Enabling 75% complete
Clinical 0% complete

Exon 51 (Exon 51 Skipping Oligonucleotide)

Duchenne Muscular Dystrophy
Discovery 100% complete
Lead Optimization 100% complete
IND Enabling 30% complete
Clinical 0% complete

Myotonic Dystrophy Type 1 (DM1)

VX-670 (Oligonucleotide) 1

Myotonic Dystrophy Type 1
Discovery 100% complete
Lead Optimization 100% complete
IND Enabling 100% complete
Clinical 40% complete

Pipeline Expansion

Undisclosed Ocular

Discovery 100% complete
Lead Optimization 90% complete
IND Enabling 0% complete
Clinical 0% complete

Undisclosed Programs

Discovery 100% complete
Lead Optimization 55% complete
IND Enabling 0% complete
Clinical 0% complete

Platform Expansion

Discovery 100% complete
Lead Optimization 0% complete
IND Enabling 0% complete
Clinical 0% complete
References
  1. 1.

    In collaboration with

    Vertex Pharmaceuticals